PE20050880A1 - Proceso para reducir la cantidad de 14-hidroxicodeinona en una preparacion de clorhidrato de oxicodona - Google Patents

Proceso para reducir la cantidad de 14-hidroxicodeinona en una preparacion de clorhidrato de oxicodona

Info

Publication number
PE20050880A1
PE20050880A1 PE2005000361A PE2005000361A PE20050880A1 PE 20050880 A1 PE20050880 A1 PE 20050880A1 PE 2005000361 A PE2005000361 A PE 2005000361A PE 2005000361 A PE2005000361 A PE 2005000361A PE 20050880 A1 PE20050880 A1 PE 20050880A1
Authority
PE
Peru
Prior art keywords
oxycodone
hydroxycodeinone
composition
amount
hydrochloride
Prior art date
Application number
PE2005000361A
Other languages
English (en)
Spanish (es)
Inventor
Robert Chapman
Lonn S Rider
Qi Hong
Donald Kyle
Robert Kupper
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35124996&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050880(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of PE20050880A1 publication Critical patent/PE20050880A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
PE2005000361A 2004-03-30 2005-03-29 Proceso para reducir la cantidad de 14-hidroxicodeinona en una preparacion de clorhidrato de oxicodona PE20050880A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US55749204P 2004-03-30 2004-03-30
US60153404P 2004-08-13 2004-08-13
US62007204P 2004-10-18 2004-10-18
US64862505P 2005-01-31 2005-01-31
US65177805P 2005-02-10 2005-02-10

Publications (1)

Publication Number Publication Date
PE20050880A1 true PE20050880A1 (es) 2005-11-16

Family

ID=35124996

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000361A PE20050880A1 (es) 2004-03-30 2005-03-29 Proceso para reducir la cantidad de 14-hidroxicodeinona en una preparacion de clorhidrato de oxicodona

Country Status (38)

Country Link
US (35) US7129248B2 (enExample)
EP (7) EP2305683B2 (enExample)
JP (8) JP4912294B2 (enExample)
KR (12) KR20150046393A (enExample)
CN (5) CN102127086B (enExample)
AP (1) AP2232A (enExample)
AR (1) AR049012A1 (enExample)
AT (2) ATE501150T1 (enExample)
AU (2) AU2005230826C1 (enExample)
BR (1) BRPI0508758B8 (enExample)
CA (3) CA2774121C (enExample)
CR (2) CR8593A (enExample)
CY (5) CY1111487T1 (enExample)
DE (2) DE202005021371U1 (enExample)
DK (6) DK2426132T3 (enExample)
EA (1) EA013208B1 (enExample)
EC (1) ECSP066953A (enExample)
ES (6) ES2566363T3 (enExample)
FI (1) FI7843U1 (enExample)
HR (5) HRP20110425T4 (enExample)
HU (3) HUE029913T2 (enExample)
IL (8) IL178038A (enExample)
LT (2) LT2314589T (enExample)
MA (1) MA28492B1 (enExample)
ME (4) ME03068B (enExample)
MX (2) MX363228B (enExample)
MY (3) MY154985A (enExample)
NO (1) NO337669B1 (enExample)
NZ (3) NZ601326A (enExample)
PE (1) PE20050880A1 (enExample)
PL (5) PL1730151T5 (enExample)
PT (5) PT2319846T (enExample)
RS (5) RS57000B1 (enExample)
SG (3) SG170735A1 (enExample)
SI (5) SI2305683T1 (enExample)
TW (3) TWI483944B (enExample)
WO (1) WO2005097801A1 (enExample)
ZA (1) ZA200607181B (enExample)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
WO2005016313A1 (de) * 2003-08-06 2005-02-24 Grünenthal GmbH Gegen missbrauch gesicherte darreichungsform
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) * 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
TWI483944B (zh) * 2004-03-30 2015-05-11 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032049A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
GB0421149D0 (en) * 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
PT1861405E (pt) * 2005-03-04 2009-07-27 Euro Celtique Sa Método de diminuír a quantidade de cetonas insaturadas em alfa-beta numa composição de opiáceos
WO2007011819A2 (en) * 2005-07-15 2007-01-25 The Penn State Research Foundation Ferritin as a therapeutic target in abnormal cells
EP1971607A2 (en) * 2005-11-22 2008-09-24 Controlled Chemicals, Inc. Processes for reducing contaminating michael acceptor levels in oxycodone and other compositions
US20070117826A1 (en) * 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
AU2007224221B2 (en) * 2006-03-02 2013-02-14 SpecGx LLC Processes for preparing morphinan-6-one products with low levels of alpha, beta-unsaturated ketone compounds
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US20080125592A1 (en) * 2006-10-17 2008-05-29 Penick Corporation Process for preparing oxymorphone, naltrexone, and buprenorphine
DK2073636T3 (da) * 2006-10-17 2012-11-19 Penick Corp Fremgangsmåde til fremstilling af oxymorphon
CA2674915C (en) 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone
WO2008070658A1 (en) * 2006-12-04 2008-06-12 Noramco, Inc. Process for preparing oxycodone having reduced levels of 14-hydroxycodeinone
CA2671551C (en) * 2006-12-04 2015-02-10 Noramco, Inc. Process for reducing impurities in oxycodone base
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
PL2125824T5 (pl) * 2007-03-23 2024-11-04 SpecGx LLC Ulepszony sposób wytwarzania oksymorfonu z oripawiny
AU2008241528B2 (en) * 2007-04-16 2013-07-04 Mallinckrodt Llc Novel opiate reduction utilizing catalytic hydrogen transfer reaction
EP2249811A1 (en) 2008-01-25 2010-11-17 Grünenthal GmbH Pharmaceutical dosage form
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
CA2720108C (en) * 2008-03-11 2016-06-07 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
NZ588863A (en) 2008-05-09 2012-08-31 Gruenenthal Chemie Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
RU2523896C2 (ru) * 2008-09-18 2014-07-27 ПУРДЬЮ ФАРМА Эл.Пи. Фармацевтические лекарственные формы, содержащие поли-(эпсилон-капролактон)
CN102573806B (zh) 2009-07-22 2015-02-25 格吕伦塔尔有限公司 用于对氧化敏感的阿片类物质的抗破坏剂型
PE20121067A1 (es) * 2009-07-22 2012-09-05 Gruenenthal Chemie Forma de dosificacion de liberacion controlada extruida por fusion en caliente
AU2010286354A1 (en) * 2009-08-31 2012-04-19 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
ES2569925T3 (es) 2009-09-30 2016-05-13 Acura Pharmaceuticals, Inc. Métodos y composiciones de disuasión del abuso
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
ES2606227T3 (es) * 2010-02-03 2017-03-23 Grünenthal GmbH Preparación de una composición farmacéutica en polvo mediante una extrusora
EP2377866B1 (en) 2010-03-23 2014-02-26 Siegfried AG Preparation of low impurity opiates in a continuous flow reactor
BR112012028773A2 (pt) 2010-05-10 2016-07-19 Euro Celtique Sa composições farmacêuticas compreendendo hidromorfona e naloxona
AU2011252041B2 (en) 2010-05-10 2014-04-03 Euro-Celtique S.A. Combination of active loaded granules with additional actives
AU2011252040C1 (en) 2010-05-10 2015-04-02 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
TWI478928B (zh) 2010-06-11 2015-04-01 Rhodes Technologies 用於製備ｎ－烯丙基化合物之過渡金屬催化的製程及其用途
EP2580218B1 (en) 2010-06-11 2015-02-25 Rhodes Technologies Process for n-dealkylation of tertiary amines
CA2804101C (en) 2010-07-02 2021-01-19 Johnson Matthey Public Limited Company Process for the synthesis and purification of oxycodone
US8912781B2 (en) * 2010-07-30 2014-12-16 Cirrus Logic, Inc. Integrated circuit switching power supply controller with selectable buck mode operation
PL2611425T3 (pl) 2010-09-02 2014-09-30 Gruenenthal Gmbh Odporna na ingerencję postać dawki zawierająca polimer anionowy
PL2611426T3 (pl) 2010-09-02 2014-09-30 Gruenenthal Gmbh Postać dawkowania zawierająca nieorganiczne sole, odporna na zgniatanie
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
HRP20171458T1 (hr) 2011-07-29 2017-11-17 Grünenthal GmbH Tableta otporna na mijenjanje koja pruža neposredno oslobađanje lijeka
ES2655900T3 (es) 2011-07-29 2018-02-22 Grünenthal GmbH Pastilla a prueba de manipulación que proporciona una liberación inmediata de un medicamento
US9414988B2 (en) 2011-09-05 2016-08-16 Siegfried Ltd. Kit comprising a packaging material and a solid pharmaceutical or nutraceutical product contained in the packaging material
JP6110384B2 (ja) 2011-09-16 2017-04-05 パーデュー ファーマ エルピー 不正改変抵抗性医薬製剤
US20140294947A1 (en) 2011-09-16 2014-10-02 Purdue Pharma L.P. Tamper resistant immediate release formulations
US20150265536A1 (en) 2011-12-09 2015-09-24 Purdue Pharma L.P. Pharmaceutical dosage forms comprising poly(epsilon-caprolactone) and polyethylene oxide
EP2819656A1 (en) 2012-02-28 2015-01-07 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
EP2819653B1 (en) 2012-03-02 2017-01-11 Rhodes Pharmaceuticals L.P. Tamper resistant immediate release formulations
SG11201406025UA (en) 2012-04-17 2014-11-27 Purdue Pharma Lp Systems and methods for treating an opioid-induced adverse pharmacodynamic response
PT2838512T (pt) 2012-04-18 2018-11-09 Gruenenthal Gmbh Forma farmacêutica resistente à adulteração e resistente à libertação inesperada de alta quantidade (dose-dumping)
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
EP2872121B1 (en) 2012-07-12 2018-09-05 SpecGx LLC Extended release, abuse deterrent pharmaceutical compositions
JP6236446B2 (ja) 2012-07-16 2017-11-22 ローズ テクノロジーズ 改善されたオピオイド合成方法
ES2647949T3 (es) * 2012-07-16 2017-12-27 Rhodes Technologies Proceso para la síntesis mejorada de opioides
SI2880037T1 (sl) * 2012-08-03 2019-04-30 Johnson Matthey Public Limited Company Postopek za pripravo oksikodona
MX392839B (es) 2012-11-30 2025-03-24 Acura Pharmaceuticals Inc Liberacion autorregulada de ingrediente farmaceutico activo.
WO2014123899A1 (en) 2013-02-05 2014-08-14 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9770710B2 (en) 2013-02-20 2017-09-26 University Of Washington Through Its Center For Commercialization Hydrogenation and disproportionation catalysis
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
MX2015016254A (es) 2013-05-29 2016-04-20 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
EP3003279A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
MX368846B (es) 2013-07-12 2019-10-18 Gruenenthal Gmbh Forma de dosificación resistente a la alteración que contiene polímero de acetato de etilen-vinilo.
GB201313211D0 (en) 2013-07-24 2013-09-04 Cambrex Karlskoga Ab New process
GB201313915D0 (en) * 2013-08-02 2013-09-18 Johnson Matthey Plc Process
BR112016002079A2 (pt) 2013-08-02 2017-09-05 Johnson Matthey Plc Processo para preparação de um aditivo ácido de oximorfona, solução aquosa de aditivo ácido de oximorfona, aditivo ácido de oximorfona sólido, e, alcaloide de oximorfona sólido
ES2741810T3 (es) 2013-11-07 2020-02-12 SpecGx LLC Producción de 6-hidroximorfinanos sin el aislamiento de intermedios
CN105916505A (zh) 2013-11-13 2016-08-31 欧洲凯尔特公司 用于治疗疼痛和阿片样物质肠功能障碍综合征的氢吗啡酮和纳洛酮
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
US10227354B2 (en) 2013-12-18 2019-03-12 Cody Laboratories, Inc. Conversion of oxycodone base to oxycodone hydrochloride
US9062062B1 (en) 2013-12-18 2015-06-23 Cody Laboratories, Inc. Synthesis of oxycodone hydrochloride
US8846923B1 (en) 2013-12-18 2014-09-30 Cody Laboratories, Inc. Preparation of 14-hydroxycodeinone sulfate
MX374394B (es) 2014-01-15 2025-03-06 Rhodes Tech Proceso para la sintesis mejorada de oxicodona.
ES2672795T3 (es) 2014-01-15 2018-06-18 Rhodes Technologies Proceso para la síntesis mejorada de oximorfona
CA2938699A1 (en) 2014-02-05 2015-08-13 Kashiv Pharma Llc Abuse-resistant drug formulations with built-in overdose protection
EP3122336A4 (en) 2014-03-26 2017-10-25 Sun Pharma Advanced Research Company Ltd Abuse deterrent immediate release biphasic matrix solid dosage form
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
JP2017516789A (ja) 2014-05-26 2017-06-22 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エタノール過量放出に対して防護されている多粒子
MA40332A (fr) * 2014-07-09 2021-04-28 Rhodes Tech Réduction des niveaux de cétone alpha, beta-insaturée dans des compositions de dérivés de morphinane
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
US20160052932A1 (en) 2014-08-25 2016-02-25 Johnson Matthey Public Limited Company Processes for Making Opioids Including 14-Hydroxycodeinone and 14-hydroxymorphinone
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CN105777766B (zh) * 2014-12-15 2017-11-24 北大方正集团有限公司 Delta‑7溴甲纳曲酮的制备方法
US9918979B2 (en) 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
AU2016251854A1 (en) 2015-04-24 2017-10-19 Grunenthal Gmbh Tamper-resistant dosage form with immediate release and resistance against solvent extraction
GB201513203D0 (en) 2015-07-27 2015-09-09 Cambrex Charles City Inc New process
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
EP3346991A1 (en) 2015-09-10 2018-07-18 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US20180104236A1 (en) 2016-09-26 2018-04-19 Euro-Celtique S. A. Methods of treatment comprising administering a high daily dose of oxycodone and naloxone in a 2:1 weight ratio
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
CN110770238B (zh) * 2017-06-20 2022-10-04 庄信万丰股份有限公司 用于从14-羟可待因酮制备盐酸氧可酮的氢化方法
US12201629B2 (en) 2017-06-30 2025-01-21 Purdue Pharma L.P. Method of treatment and dosage forms thereof
CN110330500B (zh) * 2019-07-12 2021-11-23 宜昌人福药业有限责任公司 一种6β-羟基-7,8-二氢-吗啡衍生物的立体选择性合成方法
CN113009060B (zh) * 2021-02-24 2022-10-21 西南药业股份有限公司 高效液相色谱法测定盐酸羟考酮含量的方法

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE286431C (enExample)
US100000A (en) * 1870-02-22 Improved sun-bonnet for horses
US420098A (en) * 1890-01-28 Mowing-machine
US1468805A (en) 1923-09-25 Htabtin ereund
US105553A (en) 1870-07-19 Improvement in kettle for melting, mixing, and casting metals
DE296916C (enExample) *
US1485673A (en) * 1924-03-04 Ministrator
US710223A (en) * 1901-06-10 1902-09-30 Thew Automatic Shovel Company Power-shovel.
SU64699A1 (ru) 1944-01-26 1944-11-30 А.И. Лютенберг Способ получени сол нокислого дигидрооксикодеинона
ES212554A1 (es) 1953-12-01 1954-08-16 Casanovas Albajes Cesar Un procedimiento para la obtención de un vidrio orgánico
US2772270A (en) 1954-10-21 1956-11-27 M J Lewenstein 14-hydroxymorphinone and 8, 14-dihydroxydihydromorphinone
US2806033A (en) 1955-08-03 1957-09-10 Lewenstein Morphine derivative
US3173878A (en) * 1960-02-26 1965-03-16 Ibm Process of making microcapsules
US3173876A (en) * 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (enExample) 1960-11-29
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3916898A (en) 1964-05-20 1975-11-04 Searle & Co Administration of medicaments and the like
NL6714885A (enExample) 1967-11-02 1969-05-06
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3905981A (en) * 1973-10-12 1975-09-16 Research Corp N-dealkylation of tertiary amines
US3894026A (en) 1973-10-16 1975-07-08 Merck & Co Inc Production of thebaine
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US3984026A (en) * 1976-03-26 1976-10-05 Shoup Russel W Combined can opening and sealing device
US4045440A (en) 1976-09-16 1977-08-30 The United States Of America As Represented By The Department Of Health, Education And Welfare Method of producing thebaine from codeine and oripavine from morphine
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4272540A (en) * 1979-04-24 1981-06-09 Sisa, Incorporated 14-Methoxymorphinan-6-one compounds and therapeutic methods of treating pain and drug dependence with them
US4370333A (en) 1981-06-29 1983-01-25 Sisa, Incorporated 17-Cyclopropylmethyl-3-hydroxy-14-methoxy 7α-methyl-morphinan-6-one and therapeutic method of treating pain with it
US4795813A (en) * 1981-08-17 1989-01-03 The Florida Board Of Regents On Behalf Of The Florida State University Synthesis of derivatives of codeine and other 3-O-alkylmorphines
US5112975A (en) 1984-03-27 1992-05-12 Mallinckrodt Specialty Chemicals Company Preparation of noroxymorphone from morphine
US4639520A (en) 1984-03-27 1987-01-27 Mallinckrodt, Inc. Preparation of 14-hydroxy-N-ethoxy-carbonyl-norcodeinone
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4810699A (en) * 1987-02-20 1989-03-07 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano[3,4,-b]indole-1-acetic acids, pharmaceutical compositions containing them, and methods for treating inflammatory conditions and for analgesic purposes using them
US4810669A (en) * 1987-07-07 1989-03-07 Oki Electric Industry Co., Ltd. Method of fabricating a semiconductor device
DE3812567A1 (de) 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
HU208633B (en) 1991-02-04 1993-12-28 Alkaloida Vegyeszeti Gyar Process for production of analgetic compositions as applicable for blocking of opioid-binding spaces /2-receptors/ causing respiration depression
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5324351A (en) 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
JP3433871B2 (ja) * 1996-01-26 2003-08-04 株式会社デンソー 集積化半導体歪みセンサ及びその製造方法
DE09003265T1 (de) 1996-06-26 2010-04-29 Board of Regents, The University of Texas System, Austin Extrudierbare pharmazeutische Schmelzklebstoffformulierung
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
ES2121554B1 (es) * 1996-12-23 1999-06-16 Univ Santiago Compostela Procedimiento de obtencion de 14-hidroximofinonas mediante fotooxidac ion de alcaloides morfinicos con sistema alcoxidienico en el anillo c.
GB9713703D0 (en) 1997-06-30 1997-09-03 Johnson Matthey Plc Preparation of opiates
GB9717629D0 (en) 1997-08-21 1997-10-22 Johnson Matthey Plc Removal of residual organic solvents
US6710223B1 (en) 1997-09-10 2004-03-23 The Procter & Gamble Company Method for improving skin condition
GB9805516D0 (en) 1998-03-17 1998-05-13 Johnson Matthey Plc Preparation of opiates
AU1426200A (en) * 1998-10-14 2000-05-01 Amic Ab A matrix and method of producing said matrix
US6177567B1 (en) * 1999-10-15 2001-01-23 Boehringer Ingelheim Chemicals, Inc. Method for preparing oxycodone
US6284769B1 (en) * 1999-12-03 2001-09-04 The Board Of Trustees Of The University Of Illinois Nonpeptide kappa opioid receptor antagonists
US6133132A (en) * 2000-01-20 2000-10-17 Advanced Micro Devices, Inc. Method for controlling transistor spacer width
ATE431145T1 (de) * 2000-02-08 2009-05-15 Euro Celtique Sa Missbrauchssichere orale opioid-agonist zubereitungen
WO2001092188A1 (en) 2000-05-29 2001-12-06 Shionogi & Co., Ltd. Method for labeling with tritium
US7200357B2 (en) * 2000-10-20 2007-04-03 Universal Electronics Inc. Automotive storage and playback device and method for using the same
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
EP1709957A3 (en) * 2001-06-05 2007-02-14 Control Delivery Systems Sustained-release analgesic compounds
CN100356907C (zh) 2001-06-08 2007-12-26 恩德制药公司 利用丙烯酸酯聚合物的控释剂型和其制备方法
DK1416842T3 (da) 2001-07-18 2009-03-16 Euro Celtique Sa Farmaceutiske kombinationer af oxycodon og naloxon
WO2003059423A1 (en) * 2002-01-15 2003-07-24 Aerogen, Inc. Systems and methods for clearing aerosols from the effective anatomic dead space
WO2003082204A2 (en) * 2002-03-26 2003-10-09 Euro-Celtique S.A. Sustained-release gel coated compositions
CN1665482A (zh) * 2002-04-29 2005-09-07 阿尔扎公司 羟可待酮控制输送给药的方法和剂型
WO2003101132A1 (en) * 2002-05-27 2003-12-04 Ntt Docomo, Inc. Mobile communication system, transmission station, reception station, relay station, communication path deciding method, and communication path deciding program
JP2005528423A (ja) 2002-05-31 2005-09-22 アルザ・コーポレーシヨン オキシコドンの変動性投薬用量の浸透圧的送達のための剤形および組成物
AU2003247876B2 (en) * 2002-07-05 2006-10-05 Collegium Pharmaceutical, Inc Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US20040058946A1 (en) * 2002-07-05 2004-03-25 Buchwald Stephen L. Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
WO2004016618A1 (en) * 2002-08-15 2004-02-26 Noramco, Inc. Oxycodone-hydrochloride polymorhs
US7192966B2 (en) 2002-11-15 2007-03-20 Branded Products For The Future Pharmaceutical composition
JP2006515861A (ja) * 2002-11-29 2006-06-08 フォレスト ラボラトリーズ インコーポレーテッド イブプロフェンとオキシコドンを含有する単位剤形での急性痛の治療方法
FR2850576B1 (fr) * 2003-02-05 2007-03-23 Ethypharm Sa Composition comprenant un melange de principes actifs, et procede de preparation
MXPA05009757A (es) 2003-03-13 2005-12-05 Controlled Chemicals Inc Conjugados de oxicodona con menor potencial de abuso y duracion de accion extendida.
US6864370B1 (en) * 2003-06-05 2005-03-08 Zhaiwei Lin Process for manufacturing oxycodone
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
TWI483944B (zh) * 2004-03-30 2015-05-11 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
US20070172958A1 (en) * 2004-03-30 2007-07-26 Euro-Celtique S.A. Methods for detecting 14-hydroxy codeinone and codeinone
US20050226929A1 (en) 2004-04-12 2005-10-13 Jianbo Xie Controlled release opioid analgesic formulation
JP5329083B2 (ja) 2004-06-25 2013-10-30 テッセラ，インコーポレイテッド ポストおよびパッドを有する部品
GB0421149D0 (en) 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
PT1861405E (pt) 2005-03-04 2009-07-27 Euro Celtique Sa Método de diminuír a quantidade de cetonas insaturadas em alfa-beta numa composição de opiáceos
WO2006138020A2 (en) 2005-06-16 2006-12-28 Mallinckrodt Inc. A synthetic route to 14-hydroxyl opiates through 1-halo-thebaine or analogs
EP1971607A2 (en) 2005-11-22 2008-09-24 Controlled Chemicals, Inc. Processes for reducing contaminating michael acceptor levels in oxycodone and other compositions
US20070117826A1 (en) 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
AU2007224221B2 (en) 2006-03-02 2013-02-14 SpecGx LLC Processes for preparing morphinan-6-one products with low levels of alpha, beta-unsaturated ketone compounds
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
WO2008070658A1 (en) * 2006-12-04 2008-06-12 Noramco, Inc. Process for preparing oxycodone having reduced levels of 14-hydroxycodeinone
CA2671551C (en) * 2006-12-04 2015-02-10 Noramco, Inc. Process for reducing impurities in oxycodone base
GB2450691A (en) 2007-07-02 2009-01-07 Alpharma Aps One-pot preparation of oxycodone from thebaine
CA2804101C (en) 2010-07-02 2021-01-19 Johnson Matthey Public Limited Company Process for the synthesis and purification of oxycodone
US9062062B1 (en) * 2013-12-18 2015-06-23 Cody Laboratories, Inc. Synthesis of oxycodone hydrochloride

Also Published As

Publication number Publication date
NO337669B1 (no) 2016-05-30
SG170736A1 (en) 2011-05-30
CY1117228T1 (el) 2017-04-05
HK1155729A1 (en) 2012-05-25
CA2913355C (en) 2021-04-20
KR20140133615A (ko) 2014-11-19
CN102887903B (zh) 2016-01-27
HRP20160885T1 (hr) 2016-09-23
AP2232A (en) 2011-05-04
CN102127086B (zh) 2013-11-27
AU2005230826A1 (en) 2005-10-20
US20160251364A1 (en) 2016-09-01
US20180022754A1 (en) 2018-01-25
CY1120171T1 (el) 2018-12-12
HUE028233T2 (en) 2016-12-28
US20150265597A1 (en) 2015-09-24
SI1730151T1 (sl) 2011-06-30
DK1730151T4 (da) 2020-10-19
JP6503392B2 (ja) 2019-04-17
ES2362282T3 (es) 2011-06-30
US20160175299A1 (en) 2016-06-23
HUE036451T2 (hu) 2018-07-30
US20200087316A1 (en) 2020-03-19
TWI483944B (zh) 2015-05-11
KR100993911B1 (ko) 2010-11-11
US20110207762A1 (en) 2011-08-25
HRP20110425T4 (hr) 2020-11-27
EP2319846A1 (en) 2011-05-11
KR101200700B1 (ko) 2012-11-13
DK1730151T3 (da) 2011-06-20
HRP20180407T1 (hr) 2018-04-20
KR20090104145A (ko) 2009-10-05
NO20064935L (no) 2006-12-18
ME01299B (me) 2011-10-31
US11384091B2 (en) 2022-07-12
RS53891B1 (sr) 2015-08-31
PT2426132E (pt) 2016-03-31
US20070179169A1 (en) 2007-08-02
EP2311839A1 (en) 2011-04-20
IL214050A0 (en) 2011-08-31
IL235298A (en) 2016-11-30
PT2316837T (pt) 2018-04-02
ES2362282T5 (es) 2021-06-24
TWI365880B (en) 2012-06-11
US7674800B2 (en) 2010-03-09
RS54941B1 (sr) 2016-11-30
EP2314589B1 (en) 2022-12-28
AP2006003738A0 (en) 2006-10-31
US20160176889A1 (en) 2016-06-23
ME02411B (me) 2016-09-20
PL2316837T3 (pl) 2018-07-31
US10689389B2 (en) 2020-06-23
EA200601520A1 (ru) 2007-02-27
US10259819B2 (en) 2019-04-16
PT2319846T (pt) 2016-08-12
IL241117B (en) 2020-06-30
KR100930730B1 (ko) 2009-12-09
US20160175300A1 (en) 2016-06-23
BRPI0508758B1 (pt) 2018-10-09
EA013208B1 (ru) 2010-04-30
US20160264588A1 (en) 2016-09-15
SI2305683T1 (sl) 2015-04-30
US20160185788A1 (en) 2016-06-30
ES2566363T3 (es) 2016-04-12
HRP20150358T1 (hr) 2015-05-08
MY172063A (en) 2019-11-13
US20160185789A1 (en) 2016-06-30
CA2774121C (en) 2016-02-16
EP1730151B2 (en) 2020-09-16
IL213890A0 (en) 2011-07-31
KR20100069719A (ko) 2010-06-24
PL1730151T5 (pl) 2023-09-18
MY143205A (en) 2011-03-31
JP2014139205A (ja) 2014-07-31
SI2426132T1 (sl) 2016-04-29
US20060173029A1 (en) 2006-08-03
CN102838607B (zh) 2016-08-03
US9777011B2 (en) 2017-10-03
EP2305683A1 (en) 2011-04-06
JP2007531756A (ja) 2007-11-08
US20090227615A1 (en) 2009-09-10
CN101812065B (zh) 2012-03-28
HK1098745A1 (en) 2007-07-27
US9522919B2 (en) 2016-12-20
EP2305683B2 (en) 2024-09-11
KR20070022033A (ko) 2007-02-23
US20070117831A1 (en) 2007-05-24
CA2557845A1 (en) 2005-10-20
AR049012A1 (es) 2006-06-21
CN102887903A (zh) 2013-01-23
KR20130020962A (ko) 2013-03-04
SG10201406658VA (en) 2014-12-30
CN1960994A (zh) 2007-05-09
IL241117A0 (en) 2015-11-30
IL214050A (en) 2013-09-30
US20130005977A1 (en) 2013-01-03
MA28492B1 (fr) 2007-03-01
IL178038A (en) 2015-10-29
TW201231469A (en) 2012-08-01
NZ549430A (en) 2010-05-28
ATE501150T1 (de) 2011-03-15
IL213888A0 (en) 2011-07-31
RS54598B1 (sr) 2016-08-31
US20160251365A1 (en) 2016-09-01
ECSP066953A (es) 2006-12-20
ME03068B (me) 2019-01-20
KR101410141B1 (ko) 2014-06-25
CN101812065A (zh) 2010-08-25
AT9952U1 (de) 2008-06-15
EP2305683B8 (en) 2015-03-04
KR20200000499A (ko) 2020-01-02
AU2009200335A1 (en) 2009-02-26
DK2426132T3 (en) 2016-04-04
TW200540177A (en) 2005-12-16
US20160250205A1 (en) 2016-09-01
HUE029913T2 (en) 2017-04-28
LT2314589T (lt) 2023-06-12
SI2319846T1 (sl) 2016-08-31
RS51693B (sr) 2011-10-31
JP5378486B2 (ja) 2013-12-25
US10696684B2 (en) 2020-06-30
US20210198268A1 (en) 2021-07-01
RS57000B1 (sr) 2018-05-31
TW201509943A (zh) 2015-03-16
HK1155728A1 (en) 2012-05-25
CY1117841T1 (el) 2017-05-17
JP2017125052A (ja) 2017-07-20
JP2012188439A (ja) 2012-10-04
US20160176888A1 (en) 2016-06-23
ME02482B (me) 2017-02-20
KR20140021716A (ko) 2014-02-20
NZ602862A (en) 2014-01-31
US11236098B2 (en) 2022-02-01
HRP20110425T1 (en) 2011-07-31
FIU20070284U0 (fi) 2007-07-04
US20100152449A1 (en) 2010-06-17
KR20120106784A (ko) 2012-09-26
EP2305683B1 (en) 2015-01-28
ES2938727T3 (es) 2023-04-14
US20160185790A1 (en) 2016-06-30
JP5118223B2 (ja) 2013-01-16
CR8593A (es) 2007-07-19
AU2005230826B2 (en) 2008-11-06
US20160175298A1 (en) 2016-06-23
US9073933B2 (en) 2015-07-07
CN102127086A (zh) 2011-07-20
EP2314589A1 (en) 2011-04-27
JP2015187134A (ja) 2015-10-29
PT2305683E (pt) 2015-05-18
US20150265598A1 (en) 2015-09-24
US7129248B2 (en) 2006-10-31
WO2005097801A1 (en) 2005-10-20
IL213891A0 (en) 2011-07-31
CY1111487T1 (el) 2015-08-05
IL213889A0 (en) 2011-07-31
KR20110110377A (ko) 2011-10-06
KR20150046393A (ko) 2015-04-29
US20070117830A1 (en) 2007-05-24
CY1116327T1 (el) 2017-02-08
EP1730151A1 (en) 2006-12-13
US20230159548A1 (en) 2023-05-25
CA2557845C (en) 2013-10-01
US20190161492A1 (en) 2019-05-30
CA2774121A1 (en) 2005-10-20
AU2009200335B2 (en) 2011-07-28
CN102838607A (zh) 2012-12-26
ES2665287T3 (es) 2018-04-25
MX363228B (es) 2019-03-15
MY154985A (en) 2015-08-28
US20050222188A1 (en) 2005-10-06
EP2426132B1 (en) 2016-01-13
KR20180088505A (ko) 2018-08-03
JP5543991B2 (ja) 2014-07-09
US20230365578A1 (en) 2023-11-16
US20210094963A1 (en) 2021-04-01
KR20120046309A (ko) 2012-05-09
EP2316837A1 (en) 2011-05-04
US8822687B2 (en) 2014-09-02
EP1730151A4 (en) 2007-05-23
US20160250204A1 (en) 2016-09-01
IL213890A (en) 2015-10-29
DE602005026786D1 (de) 2011-04-21
DK2305683T3 (en) 2015-04-07
PT1730151E (pt) 2011-06-01
US12060361B2 (en) 2024-08-13
AU2005230826C1 (en) 2014-10-16
US20070117829A1 (en) 2007-05-24
CR20110376A (es) 2011-09-19
JP2018184462A (ja) 2018-11-22
FI7843U1 (fi) 2008-04-28
PL2305683T3 (pl) 2015-07-31
US7683072B2 (en) 2010-03-23
US20200062772A1 (en) 2020-02-27
DE202005021371U1 (de) 2007-10-25
DK200700214U1 (da) 2007-11-23
EP2316837B1 (en) 2018-01-10
DK2319846T3 (en) 2016-08-15
RS51693B2 (sr) 2021-02-26
US10407434B2 (en) 2019-09-10
BRPI0508758B8 (pt) 2021-05-25
IL213889A (en) 2012-06-28
JP4912294B2 (ja) 2012-04-11
LT2316837T (lt) 2018-04-10
US20150258086A1 (en) 2015-09-17
NZ601326A (en) 2013-10-25
SG170735A1 (en) 2011-05-30
JP2011157370A (ja) 2011-08-18
US7674798B2 (en) 2010-03-09
IL178038A0 (en) 2006-12-31
PL2319846T3 (pl) 2016-12-30
MX2020008878A (es) 2020-11-09
US20160251363A1 (en) 2016-09-01
ZA200607181B (en) 2007-11-28
SI2316837T1 (en) 2018-05-31
PL1730151T3 (pl) 2011-08-31
CA2913355A1 (en) 2005-10-20
BRPI0508758A (pt) 2007-08-28
EP2426132A1 (en) 2012-03-07
US7674799B2 (en) 2010-03-09
ES2585576T3 (es) 2016-10-06
JP2012072162A (ja) 2012-04-12
DK2316837T3 (en) 2018-04-16
SI1730151T2 (sl) 2021-03-31
ES2535618T3 (es) 2015-05-13
PL2426132T3 (pl) 2016-06-30
CN1960994B (zh) 2012-09-05
DK200700214U3 (da) 2008-02-08
EP1730151B1 (en) 2011-03-09
EP2319846B1 (en) 2016-05-04
HRP20160223T1 (hr) 2016-03-25

Similar Documents

Publication Publication Date Title
PE20050880A1 (es) Proceso para reducir la cantidad de 14-hidroxicodeinona en una preparacion de clorhidrato de oxicodona
TW200643225A (en) Regeneration of cupric etchants and recovery of copper sulfate
TW200710081A (en) Process for producing carboxylic acid
EP1894887A3 (de) Verfahren zur Aufarbeitung einer Ätzmischung, die bei der Herstellung von hochreinem Silizium anfällt
CO6670555A2 (es) Método para recuperar oro por extracción con solvente
BRPI0401876A (pt) Processo para recuperação de catalisador de metal de um licor mãe, corrente de impurezas orgânicas com alto ponto de ebulição, corrente rica em solvente, processo para produção de uma corrente de licor mãe superconcentrado, e, composição
JP2006291352A5 (enExample)
CN102372385A (zh) 硫酸铜回收方法及硫酸铜回收装置
BR112012028507A2 (pt) processo para recuperação de etanol com extrações laterais para regular as concentrações de c3 + alcoóis
DE602005000334D1 (de) Verfahren zur herstellung von oxycodon
JOP20210055A1 (ar) عملية لتنقية وتركيز العناصر الأرضية النادرة من الجبس الفوسفوري
PE20050001A1 (es) Metodo y equipo para purificar una solucion de extraccion de un arrastre acuoso e impurezas
CO6170353A2 (es) Metodo y aparato para remover arsenico de una solucion
TW200510571A (en) High purity copper sulfate and method for production thereof
ECSP099543A (es) Método y aparato para recuperar un metal y separar el arsénico de una solución que contiene arsénico
JP2007217405A (ja) アニリンの精製方法および製造方法
ES2189764T3 (es) Proceso para la separacion y purificacion de una mezcla acuosa que tiene como componentes principales acido acetico y acido formico.
BRPI0411925A (pt) processo para separação e recuperação de ácido 3-hidroxipropiÈnico e ácido acrìlico
RU2005109425A (ru) Способ экстракции растворителем
AR047320A1 (es) Proceso de extraccion para remocion de impurezas de una corriente de purga oxidante en la sintesis de acido carboxilico
CN1123825A (zh) 一种石油馏分油氨醇脱酸工艺
KR101481366B1 (ko) 양극 슬라임으로부터 은 및 주석의 분리회수방법
MX2021007012A (es) Recuperación de valores de oro y plata de alimentos mediante extracción asistida por ultrasonido.
TW200600464A (en) Method for recovering highly pure oxalic acid aqueous solution
RU2007126478A (ru) Установка для удаления ртути из жидкого углеводорода

Legal Events

Date Code Title Description
FG Grant, registration